Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P08908 (
5-HT1A
)
5,574
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Systemic administration of the
5-HT1A
receptor agonist 8-OH-DPAT modifies 5-HT neuronal transmission via stimulation of presynaptic and postsynaptic receptors. Compared to the effects of presynaptic receptor stimulation, there are less data on the effects of postsynaptic
5-HT1A
receptors and the net effects of a stimulation of pre- and postsynaptic
5-HT1A
receptors available. We measured the neuronal activity in the rat hippocampus after systemic treatment with 8-OH-DPAT in doses (30-300 microg/kg) known to reduce 5-HT release and anxiety-like behavior in rodents. Neuronal activity was assessed by laser-induced fluorescence spectroscopy determining changes in nicotinamide adenine dinucleotide (
NADH
) fluorescence in the ventral hippocampus of anaesthetized rats in vivo.
NADH
, a co-substrate for energy transfer in the respiratory chain, mirrors mitochondrial activity. Increased
NADH
fluorescence signals lower consumption of
NADH
caused by neuronal inhibition. 8-OH-DPAT in a dose of 300 microg/kg, but not 100 microg/kg and 30 microg/kg, increased
NADH
fluorescence by maximal +27 +/- 3.5%, suggesting a decreased neuronal activity in the ventral hippocampus. The selective
5-HT1A
antagonist WAY-100635 (3 mg/kg) prevented the increased
NADH
fluorescence after 8-OH-DPAT, but had no own effect. The results show that systemic administration of the
5-HT1A
agonist 8-OH-DPAT dose-dependently affects neuronal activity in the ventral hippocampus. The dose of 300 microg/kg seemingly activates presynaptic and postsynaptic receptors with dominating inhibitory postsynaptic effects.
...
PMID:Effects of 8-OH-DPAT on hippocampal NADH fluorescence in vivo in anaesthetized rats. 1643 95